# Eurofarma Ventures

> Eurofarma Ventures is a VC fund in São Paulo backing Biotechnology and Life Science. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: São Paulo, Brazil
- Total investments: 5
- Last investment: Jan 2024
- Lead investor: 20%
- Last updated: Aug 2026

Eurofarma Ventures is a VC fund in São Paulo focused on Biotechnology and Life Science. Eurofarma Ventures operates as a venture capital arm of Eurofarma.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 100% |
| Life Science | 2 | 40% |
| Therapeutics | 2 | 40% |
| Medical | 1 | 20% |
| Chemical | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Seed | 1 | 20% |
| Series A | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 80% |
| Brazil | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Psivant Therapeutics | Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services. |  | Venture - Series Unknown | Jan 01, 2024 |  |
| gen-t | Gen-t is a platform capable of providing the map of genomic research. Gen-t was founded in 2021 and was headquartered in Sao Paulo, Brazil. | $1.3M | Seed | Oct 09, 2023 |  |
| Walden Biosciences | Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease. |  | Series B | Oct 01, 2023 |  |
| ROME Therapeutics | ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. | $72M | Series B | Sep 12, 2023 |  |
| Abata Therapeutics | Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases. | $95M | Series A | Jun 23, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 2 deals together
- [Third Rock Ventures](https://shizune.co/investors/profile/third-rock-ventures) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 1 deal together
- [ATEM Capital Fund LP](https://shizune.co/investors/profile/atem-capital) — VC Fund, 1 deal together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 1 deal together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [DOMO.VC](https://shizune.co/investors/profile/domo-invest) — VC Fund
- [Canary](https://shizune.co/investors/profile/canary-5) — VC Fund

## Featured in investor lists
- [Life Science VC Funds in Brazil](https://shizune.co/investors/life-science-vc-funds-brazil)
- [Life Science Investors in Brazil](https://shizune.co/investors/life-science-investors-brazil)

## FAQ

### What does Eurofarma Ventures invest in?

Eurofarma Ventures invests primarily in Biotechnology, Life Science and Therapeutics startups, most often at Series B and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eurofarma Ventures last invest?

The most recent investment recorded for Eurofarma Ventures closed in Jan 2024. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co